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INTRODUCTION
B
ovine pancreatic ribonuclease A (RNase A; EC
3.1.27.5) has long been studied as a model of enzyme
structure and function (reviewed by Raines
1). It is
now increasingly recognised as the archetype of an
intriguing enzyme superfamily whose actions are
closely linked to the evolution of vertebrates and which has
undergone tremendous diversiﬁcation.
2–5 Many members of
the superfamily have potent biological activities that are de-
pendent on their enzymatic activity. Among these are the
angiogenic and tumor-promoting activities of angiogenin
(Ang),
6–8 the antiviral and neurotoxic activities of eosino-
phil-derived neurotoxin (EDN)
9,10 and the cytotoxic activ-
ities of bovine seminal ribonuclease
11 and Onconase.
12 The
Inﬂuence of Naturally-Occurring 50-Pyrophosphate-Linked Substituents
on the Binding of Adenylic Inhibitors to Ribonuclease A: An X-Ray
Crystallographic Study
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ABSTRACT:
Ribonuclease A is the archetype of a functionally diverse
superfamily of vertebrate-speciﬁc ribonucleases. Inhibitors
of its action have potential use in the elucidation of the in
vivo roles of these enzymes and in the treatment of
pathologies associated therewith. Derivatives of adenosine
50-pyrophosphate are the most potent nucleotide-based
inhibitors known. Here, we use X-ray crystallography to
visualize the binding of four naturally-occurring
derivatives that contain 50-pyrophosphate-linked
extensions. 50-ATP binds with the adenine occupying the
B2 subsite in the manner of an RNA substrate but with
the g-phosphate at the P1 subsite. Diadenosine
triphosphate (Ap3A) binds with the adenine in syn
conformation, the b-phosphate as the principal P1 subsite
ligand and without order beyond the g-phosphate.
NADPH and NADP
1 bind with the adenine stacked
against an alternative rotamer of His119, the 20-
phosphate at the P1 subsite, and without order beyond the
50-a-phosphate. We also present the structure of the
complex formed with pyrophosphate ion. The structural
data enable existing kinetic data on the binding of these
compounds to a variety of ribonucleases to be rationalized
and suggest that as the complexity of the 50-linked
extension increases, the need to avoid unfavorable
contacts places limitations on the number of possible
binding modes. # 2009 Wiley Periodicals, Inc.
Biopolymers 91: 995–1008, 2009.
Keywords: enzyme inhibitor; RNase A; angiogenin;
eosinophil-derived neurotoxin; ATP; diadenosine
polyphosphates; NADPH; NADP1; pyrophosphate
Contract grant sponsor: Wellcome Trust
Contract grant number: 083191
V V C 2009 Wiley Periodicals, Inc.
Biopolymers Volume 91 / Number 12 995use of site-directed mutagenesis and broad-spectrum inhibi-
tors such as ribonuclease inhibitor (RI) protein
13 have been
invaluable in establishing the links between biological and en-
zymatic activities. However, the development of stable, low-
molecular weight inhibitors with high speciﬁcity remains a
priority for the study of individual enzymes in their natural
settings. Furthermore, such compounds may lead to agents for
the treatment of pathologies associated with ribonuclease
action, most notably anti-tumor agents directed at Ang.
8
RNase A superfamily members cleave the P-O50 bonds of
RNA speciﬁcally after pyrimidine residues.
14 Inhibition of
this action with small molecules has focused principally on
the central catalytic and substrate-binding region. This is
conventionally divided into subsites named P1,B 1, and B2,
which bind the scissile bond and the heterocyclic bases im-
mediately upstream (a pyrimidine) and downstream (prefer-
entially a purine), respectively.
14,15 One well-established line
of attack involves phosphoadenosine-based nucleotides. Such
compounds inhibit a variety of ribonucleases including
RNase A, EDN, eosinophil cationic protein (ECP), RNase 4,
Ang and, in all likelihood, many others.
16 The tightest-bind-
ing examples reported thus far are chemically-synthesized
derivatives of adenosine 50-pyrophosphate (ppA); among
these, 50-diphosphoadenosine 30-phosphate (ppA-30-p) and
its 50-phospho 20-deoxyuridine derivative (pdUppA-30-p) ex-
hibit Ki values of 10
28–10
26M when binding to RNase A,
EDN, or RNase 4.
17,18 This has been matched only by oligo
(vinylsulfonic acid), a polyanion that inhibits RNase Awith a
Ki of 0.12 lM under similar buffer conditions containing
0.1M NaCl.
19
X-ray crystallographic studies of complexes formed
between phosphoadenosine-based inhibitors and RNase
A,
20–22 EDN,
23,24 and ECP
25 have shown that these com-
pounds bind minimally to the P1 and B2 subsites but can also
make additional interactions further aﬁeld depending on the
nature of substitution. Exploration of the more peripheral
interactions may lead to the development of inhibitors that
are speciﬁc to particular ribonuclease homologs. However,
these enzyme inhibitor systems exhibit remarkable confor-
mational complexity and the conﬁdence with which inhibitor
improvements can be derived from the existing data is not
high. For example, with the RNase A inhibitor system
(which has received most attention thus far; Table I), a sim-
ple RNA-derived compound such as pA-30-p binds in the
conventional manner observed for oligonucleotide substrate
analogues
32–35 (here designated as Class Ia) but a radically
altered mode is observed upon modiﬁcation of the com-
pound with phosphate groups at the 50- and/or 20- positions.
The two key torsional parameters that characterize this are
the rotameric state of His119 (a residue that contributes to
both the P1 and B2 subsites) and the N-glycosidic torsion
angle (v) of the nucleotide. These reﬂect to a large degree the
nature of the base-stacking interaction at the B2 subsite and
the region of the inhibitor that occupies the P1 subsite.
Table I Categorized Binding of 50-Phosphoadenosine-Based Inhibitors to RNase A
Ring Stacking Partners
(B2 Subsite)
N-glycosidic Torsion
Angle, v
b P1 Subsite Representatives
His119
Rotamer
a
Adenine
Subfragment Range in Degrees Ligand Compound PDB Entry
Protein
Chain
c Reference
Class Ia A Pentacyclic ring 293–314 (high-anti)5 0-Pa pA 1Z6S A(A), B 26
pA-30-p 1O0F A, B 22
pA-20-p 1O0O B 22
Class Ib A Pentacyclic ring \293 (anti/high-anti) Not 50-Pa pA 1Z6S A(B) 26
Class II A Hexacyclic ring 31–88 (syn)5 0-Pb ppA 1O0H A 22
ppA-30-p 1AFK A, B 20
ppA-20-p 1AFL A, B 20
dUppA 1JN4 A 27
pdUppA-30-p 1QHC A, B 21
pdTppA-30-p 1U1B A, B 28
Class III B Both rings 277 (high-anti) 20-P pA-20-p 1O0O A 22
a For rotamer A, v1   1508 and v2   21008; for rotamer B, v1   2708 and v2   2608.
29
b The N-glycosidic torsion angle, v is the rotation about O40–C10–N9–C4. In RNA, v is usually anti (180–2508) or high-anti (above 2508) but rarely syn
(\1208).
30,31
c Letters in parentheses denote alternate ligand conformations.
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BiopolymersIn view of the conformational uncertainties in the binding
of adenylic nucleotides, it remains a priority to extend the
panel of inhibitor complexes for which structural data is
available. It is pertinent that several naturally-occuring nucle-
otides that possess a ppA moiety are also effective ribonucle-
ase inhibitors.
36 These include 50-ATP, P
1,P
3-bis(50-adenosyl)
triphosphate (Ap3A), NADPH, and NADP
1. We present here
the X-ray crystal structures of these compounds in com-
plex with RNase A, along with that of a pyrophosphate ion
(PPi) complex of the same. They provide new insight into
the consequences of a variety of 50-linked extensions on
the binding of adenylic nucleotides to RNase A and its
homologs, and indicate how improved inhibitors might be
developed.
RESULTS
Structural Overview
The structures of monoclinic RNase A crystals soaked with
50-ATP, Ap3A, NADPH, NADP
1, and PPi were obtained at
resolutions of 1.7, 2.4, 1.7, 1.7, and 1.8 A ˚, respectively, as
summarized in Table II. This crystal form presents two pro-
tein chains (mol A and mol B) in the asymmetric unit,
20 and,
Table II Crystallographic Statistics
RNase A 50-ATP RNase A Ap3A RNase A NADPH RNase A NADP
1 RNase A PPi
Diffraction data
X-ray wavelength (A ˚) 0.98 1.54 0.87 0.87 0.98
Resolution range
All data (A ˚) 40–1.70 40–2.40 40–1.70 40–1.70 40–1.80
Outermost shell (A ˚) 1.76–1.70 2.49–2.40 1.76–1.70 1.76–1.70 1.86–1.80
Space group C2 C2 C2 C2 C2
Unit cell dimensions
a (A ˚) 101.73 101.96 102.96 102.89 101.33
b (A ˚) 33.27 33.40 33.72 33.70 33.46
c (A ˚) 73.49 75.70 74.15 74.25 73.85
b (deg) 90.10 91.05 89.95 89.97 90.23
No. of reﬂections
Measured 64,745 22,719 83,678 156,497 66,478
Unique 26,455 9,496 27,237 27,006 22,438
Rsymm
a,b 0.078 (0.330) 0.090 (0.337) 0.031 (0.119) 0.042 (0.098) 0.092 (0.354)
I/r (I)
b 10.7 (2.3) 10.8 (2.0) 26.6 (8.1) 21.3 (10.3) 9.5 (4.2)
Completeness (%)
b 96.1 (95.8) 92.3 (94.6) 95.6 (92.3) 94.8 (88.3) 95.9 (97.1)
Wilson B-factor 31.6 39.8 23.4 21.9 30.9
Reﬁned model
Rcryst
c 0.198 0.198 0.177 0.185 0.187
Rfree
d 0.230 0.273 0.205 0.227 0.222
Deviation from ideality (r.m.s.)
Bond lengths (A ˚) 0.013 0.014 0.014 0.015 0.012
Bond angles (deg) 1.48 1.61 1.38 1.39 1.38
No. of atoms
Protein (mol A, mol B) 923, 931 907, 919 949, 953 938, 940 943, 940
Ligand (mol A, mol B) 31, 31 31, 31 27, 27 27, 27 9, 9
Water 117 36 171 151 125
Mean B-factor (A ˚ 2)
Protein (mol A, mol B) 32.5, 28.5 42.6, 34.5 23.1, 21.7 21.5, 20.5 32.2, 27.9
Ligand (mol A, mol B) 39.6, 45.9 50.9, 67.3 32.1, 39.2 28.3, 35.7 31.9, 26.2
Water 38.6 34.0 34.8 32.8 38.3
Ligand occupancy (mol A, mol B) 0.70, 0.70 1.00, 1.00 1.00, 1.00 1.00, 1.00 0.75, 1.00
a Rsymm 5 ShSi[|Ii(h) 2 hI(h)i|/ShSiIi(h)], where Ii is the ith measurement and hI(h)i is the weighted mean of all measurements of I(h).
b Values in parentheses refer to the outermost shell.
c Rcryst 5 Sh|Fo2Fc|/ShFo, where Fo and Fc are the observed and calculated structure factor amplitudes of reﬂection h, respectively.
d Rfree is equal to Rcryst for a randomly selected 5–10% of reﬂections not used in the reﬁnement.
37
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Biopolymerswith the exception of the Ap3A complex, which lacks residue
LysA1, each of the structures comprises two complete main
chains (residues 1–124). Density for residues 16–24 and 87–
90 of each chain is consistently poor, as is typical for this
crystal form. In Ramachandran plots, 94.2–96.7% of non-
Pro/Gly residues lie in the most-favored regions with only
SerB16 falling in a disfavored region. In no case is the main
chain topology perturbed signiﬁcantly by the presence of the
ligand; of the 10 protein chains, nine have C
a traces that
deviate by 0.21–0.25 A ˚ (r.m.s.) from the corresponding chain
in monoclinic unliganded RNase A (PDB entry 1AFU),
20
whereas for chain A of the Ap3A complex, the ﬁgure is
slightly higher at 0.48 A ˚ and appears to be a consequence of
the relatively low resolution of this structure.
Chemical structures, harmonized atom nomenclature,
and conserved torsion angles of the nucleotide inhibitors are
presented in Figure 1. For each of these compounds, the elec-
tron density data indicate clearly the position of one adenine
ring and 2–3 phosphate groups but not that of the interven-
ing ribosyl moiety (Figure 2). This parallels the difﬁculty
experienced in locating the ribosyl backbone atoms in many
RNA structures.
38 Plausible coordinates were derived
through crystallographic reﬁnement with REFMAC5
39 with
referral to the all-atom contact analysis of MolProbity
40 and
in the knowledge that the lever-actions of the base and phos-
phates dictate to a large degree the sugar’s conformation.
41
The position of each of the nucleotide inhibitors is better
deﬁned in mol A than in mol B. In several cases, this may be
due to the stabilizing inﬂuence of a crystal contact, as
described in more detail below.
Structure of the RNase A 50-ATP Complex
The inhibition of RNase A by simple 50-phosphorylated
adenosines becomes progressively stronger as the number of
phosphates is increased. Under equivalent conditions, Ki val-
ues for 50-AMP (pA), 50-ADP (ppA), and 50-ATP (pppA) are
80, 1.2, and 0.86 lM, respectively.
18,36 The 67-fold drop in Ki
experienced when moving from 50-AMP to 50-ADP coincides
with a radical change in nucleotide conformation (Class Ia/
Ib to Class II; Table I).
22,26 We now present the crystal struc-
ture of the RNase A 50-ATP complex. The electron density
map indicates the position of the base, the b- and the c-phos-
phate but there is signiﬁcant disorder in between (Figure 2a).
The adenine ring is positioned as in the 50-AMP complex,
stacking with His119 (rotamer A) and hydrogen-bonding
with Asn71 in a conventional (Class Ia) fashion, but a small
decrease in v coupled with a pronounced curvature of the tri-
phosphate chain brings the c- rather than the a-phosphate
into the P1 subsite (Figure 3; Table III). As such, the binding
FIGURE 1 Chemical structures, harmonized atom numbering,
and conserved torsion angles of 50-ATP, Ap3A, NADPH, and
NADP
1.
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Biopolymersmode conforms to Class Ib. The two instances of the inhibi-
tor in the asymmetric unit show modest differences in their
ribose and triphosphate conformations that permit alter-
native hydrogen-bonding arrangements. Bonds are consis-
tently made between the c-phosphate and His12, His119,
and Phe120 but involve different inhibitor atoms (Table
IV). Also, whereas in mol A there are two potential hydro-
gen bonds between the b-phosphate and Gln11, in mol B
there is one between the c-phosphate and this residue.
There are no direct interactions between the inhibitor and
symmetry-related protein atoms that might explain the
differences, and the underlying cause is not clear. Water-
mediated interactions are made with Gln11, Asn67, Val118
(mol A only), Phe120 (mol A only), and Asp121, while
Coulombic interactions link the N
f atom of Lys7 (a com-
ponent of the P2 subsite) and the polyphosphate chain,
the closest approach being 3.6 A ˚ to the b-phosphate in
mol A.
50-ATP is the ﬁrst compound containing a c-phosphate
group for which the three-dimensional details of RNase A
binding have been obtained. Previous studies on adenylic nu-
cleotides that contain a 50-pyrophosphate group (in various
states of derivatization) are consistent in their description of
a syn base conformation and in their placement of b-phos-
phate as the major P1 subsite ligand when bound to RNase A
(Class II binding). The conformation observed here for
RNase A-bound 50-ATP represents a deviation from this
pattern and offers an explanation for the stagnation in Ki
encountered when moving from 50-ADP to 50-ATP. That is,
although the Class II binding mode can support produc-
tive interactions of additional 50-b-phosphate-linked sub-
stituents (e.g., in the binding of pdUppA-30-p),
21 with 50-
ATP these are not as favorable as those involving the c-
phosphate after adoption of the anti conformation
observed here.
50-ATP also inhibits EDN, albeit  25-fold less effectively
(Ki 5 21 lM).
36 The manner in which this compound binds
to EDN (PDB entry 2C01)
24 differs from that observed here
with RNase A. A mixture of two conformations is present,
neither of which is particularly well ordered. In one of these
(conformation A), the adenine ring is bound as in RNase A,
but the P1 subsite is occupied principally by the a-phos-
phate whereas the c-phosphate is disordered. The catalytic
centers of the two proteins are highly similar, and it seems
that electronic and/or steric effects of a subtle nature are
responsible for the differences in binding. Whatever the
case, the superior inhibition of RNase A correlates with a
better-deﬁned and more extensive interaction between in-
hibitor and protein.
Structure of the RNase A Ap3A Complex
Extension of 50-ATP by attachment of a 50-linked adenosine,
thereby generating Ap3A (Figure 1), causes a 34-fold decrease
in afﬁnity (Ki 5 29 lM).
36 To ﬁnd an explanation, we deter-
FIGURE 2 Electron density maps for the nucleotide inhibitors.
Shown in stereo for (a) 50-ATP (mol A), (b) Ap3A (mol A), (c)
NADPH (mol A), (d) NADP
1 (mol A), and (e) PPi (mol B) is the
ball-and-stick structure of the reﬁned inhibitor (or fragment
thereof) superposed with the corresponding portion of the total
OMITmap calculated with SFCHECK
62 and contoured at 1.3r. The
coloring scheme is: carbon, gold; nitrogen, blue; oxygen, red; phos-
phorus, pink; electron density, green.
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BiopolymersFIGURE 3 RNase A 50-ATP complex (mol A). Shown in stereo are ball-and-stick representations
of the inhibitor and RNase A residues in and around the binding site, along with a surface represen-
tation of the enzyme. Main chain N, C, and O atoms of residues K7, Q11, H12, K41, V43, and E111
are omitted for clarity. The coloring scheme is: nucleotide carbon, gold; protein carbon, gray; nitro-
gen, blue; oxygen, red; phosphorus, pink. Spheres denote water molecules and dashed lines denote
hydrogen bonds.
Table III Conformations of the Nucleotide Inhibitors
50-ATP Ap3A NADPH NADP
1
Mol A Mol B Mol A Mol B Mol A Mol B Mol A Mol B
Torsion Angles (deg)
a
N-glycosidic bond
O40–C10–N9–C4 (v) 224 222 64 46 271 256 271 259
Conformational region anti anti syn syn high-anti high-anti high-anti high-anti
50-substituents
C50–C40–C30–O30 (d) 130 106 110 106 146 136 146 137
O50–C50–C40–C30 (c) 218 203 51 202 31 70 28 54
PA–O50–C50–C40 (b) 90 102 191 125 143 197 153 168
O3A–PA–O50–C50 (a) 215 168 302 176 86
b 53
b 81
b 73
b
PB–O3A–PA–O50 (fp1) 91 56 213 291 — — — —
O3B–PB–O3A–PA (fp2) 224 299 309 238 — — — —
PG–O3B–PB–O3A (fp3) 55 150 153 96 — — — —
O3G–PG–O3B–PB (fp4) 293
b 355
b 196
b 285
b ————
20-substituent
P20–O20–C20–C10 — — — — 130 140 131 139
P20–O20–C20–C30 — — — — 244 254 246 256
Conformational Parameters
Ribose pucker
c
P (deg) 140 352 106 19 177 147 182 149
Conformational region C20-endo C20-exo O40-endo C30-endo C20-endo C20-endo C30-exo C20-endo
a Torsion angle deﬁnitions follow IUPAC-IUB recommendations
42 where possible and are illustrated in part in Figure 1.
b Because of rotational permutations, the positions of atom O3A in NADPH/NADP
1 and atom O3G in 50-ATP/Ap3A are ambiguous. However, they have
been assigned as the most solvent-exposed oxygen and included for comparison.
c As described by Altona and Sandaralingam.
43
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Biopolymersmined the structure of the RNase A Ap3A complex. The
electron density map indicates the position of a portion of
the nucleotide corresponding to a 50-ATP moiety
(Figure 2b), and the remainder of the inhibitor is presumed
to be in no ﬁxed conformation. The visible portion has the
adenine/His119 rotamer A stacking arrangement and syn
base conformation of the Class II binding mode associated
with 50-pyrophosphate-containing adenine nucleotides
(Figure 4a; Table III). There are modest differences in the
binding of the inhibitor to the two protein chains in the
asymmetric unit. These appear to derive from a hydrogen bond
in mol A between O20 of the ribose and O
c1 of a symmetry-
related ThrB70 residue. This has negligible impact on the ade-
nine position but alters the conformation of the ribose and, to a
lesser degree, the polyphosphate chain (Table III). Two hydro-
gen bonds between the adenine and the side chain of Asn71 are
maintained, as is one between the b-phosphate and His12, and
one between the c-phosphate and Lys41 (Table IV). The N
f
atom of Lys7 is   4A ˚ away from the a-phosphate, close enough
for signiﬁcant Coulombic interactions. Differences between the
two instances of the inhibitor include a hydrogen bond between
the a-phosphate and His119 in mol A only and one between
the b-phosphate and Phe120 in mol B only.
Although they comprise the same set of atoms, RNase A-
bound 50-ATP and the ordered portion of likewise-bound
Ap3A exhibit conformations that are clearly very different
from one another. In the 50-ATP complex, the compact con-
formation of the polyphosphate chain and the tendency of
the c-phosphate toward burial among the P1 subsite residues
appears to leave little scope for the addition of a second 50-
linked adenosine (see Figure 3). A switch to the Class II bind-
ing mode, however, provides an exit route for the 50-exten-
sion, as is observed for other inhibitors such as pdUppA-30-
p.
21 The loss of 1–2 hydrogen bonds that accompanies this
change most likely contributes to the decrease in afﬁnity that
is observed when moving from 50-ATP to Ap3A.
Ap3A inhibits EDN with a similar potency (Ki 5 70
lM).
36 When bound to EDN (PDB entry 2C02),
24 the con-
Table IV Potential Hydrogen Bonds Between RNase A and the Nucleotide Inhibitors
Inhibitor Atom
Potential Hydrogen-Bonding Interactions (Protein Atom, Separation in A ˚)
a
50-ATP Ap3A NADPH NADP
1
M o lA M o lB M o lA M o lB M o lA M o lB M o lA M o lB
Adenine
N1 N71 N
d2, 3.0 N71 N
d2, 3.0 –— — — — — —
N6 N71 O
d1, 2.7 N71 O
d1, 2.8 N71 O
d1, 2.8 N71 O
d1, 3.2 (T70 O
c1, 2.9)
b — (T70 O
c1, 3.0)
b —
N7 — — N71 N
d2, 3.1 N71 N
d2, 3.2 — — — —
Ribose
O20 — — (T70 O
c1, 2.4)
b — ————
20-phosphate
OP1 — — — — H119 N
d1, 2.7 H119 N
d1, 2.7 H119 N
d1, 2.6 H119 N
d1, 2.7
OP2 — — — — H12 N
e2, 2.7 H12 N
e2, 2.7 H12 N
e2, 2.7 H12 N
e2, 2.7
— — — — F120 N, 2.9 F120 N, 2.9 F120 N, 2.9 F120 N, 2.9
OP3 — — — — (Q11 N
e2, 3.4)
c Q11 N
e2, 3.3 (Q11 N
e2, 3.5)
c Q11 N
e2, 3.3
50-a-phosphate
O2A — — H119 N
d1, 3.3 — — — — —
50-b-phosphate
O2B Q11 O
e1, 3.1 — H12 N
e2, 2.5 F120 N, 3.0 — — — —
O3B Q11 N
e2, 2.7 — — H12 N
e2, 3.2 — — — —
50-c-phosphate
O1G H12 N
e2, 2.7 H12 N
e2, 2.7 K41 N
f, 2.5 K41 N
f, 2.6 — — — —
F120 N, 3.2 F120 N, 2.9
O2G H119 N
d1, 2.7 Q11 N
e2, 2.5 — — — — — —
O3G — H119 N
d1, 2.7 — — — — — —
a Potential hydrogen bonds are listed if identiﬁed with HBPLUS
44 and corroborated by clear electron density for donor and acceptor.
b Crystal contact with symmetry-related mol B.
c Distance exceeds normal limits but is included for comparison.
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Biopolymersformation of the second adenosine moiety is likewise disor-
dered, but a syn base conformation is not observed. The rea-
son for this is the need to avoid an overlap between the O30
edge of the ribose and the side chain of Trp7 (a residue whose
counterpart in RNase A is Ala4) (Figure 4b). The a- and b-
phosphates appear to hydrogen-bond with EDN’s P1 subsite
but it was not possible to arrive at a deﬁnitive arrangement
due to disorder in the nucleotide.
24 It seems likely that
FIGURE 4 RNase A Ap3A complex (mol A). (a) Enzyme and inhibitor in the same representa-
tion and orientation as in Figure 3. The inhibitor is disordered beyond the 50-c-phosphate. (b)
Comparison with the EDN Ap3A complex (PDB entry 2C02).
24 The two complexes were super-
posed on the basis of the C
a positions of key nucleotide-binding residues (from RNase A, mol A:
Q11, H12, K41, T45, H119, and F120; from EDN: Q14, H15, K38, T42, H129, and L130). Shown in
stereo in the same orientation as in panel a are ball-and-stick representations of RNase A-bound
Ap3A (colored as in panel a), EDN-bound Ap3A (white), and neighboring EDN residues (green),
along with a surface representation of EDN. Main chain N, C, and O atoms of residues W10, Q14,
H15, K38, Q40, and D112 are omitted for clarity. The EDN-bound inhibitor is disordered beyond
the 50-b-phosphate.
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Biopolymershydrogen-bonding is less extensive than in the RNase A com-
plex and that this is compensated for by the adoption of a
more favorable base conformation to give a similar binding
afﬁnity.
Structures of the RNase A NADPH and RNase
A NADP
1 Complexes
The compound ppA-20-p is among the tightest-binding
RNase A inhibitors known (Ki 5 0.52 lM).
18 NADPH and
NADP
1 are naturally-occurring substances that contain a
ppA-20-p moiety yet are considerably less effective inhibitors
with Ki values of 12 and 63 lM, respectively.
36 Seeking an ex-
planation, we determined the crystal structures of NADPH
and NADP
1 in complex with RNase A. These reveal no
major differences between the binding of the two inhibitors
and therefore they will be treated together.
The electron density map permits modelling of a pA-20-p
moiety; no density is observed for the 50-b-phosphate, nico-
tinamide or the intervening sugar and they are presumed to
be in no ﬁxed conformation (Figures 2c and 2d). The ade-
nine ring stacks against His119 (rotamer B) and the 20-phos-
phate occupies the P1 subsite (Figure 5). This conforms to
Class III binding and matches the mode reported for pA-20-p
bound to crystalline RNase A (mol A) and EDN or to Ang in
solution.
22,23,45 Again, there are small conformational differ-
ences between the binding of the inhibitor to each of the two
protein chains in the asymmetric unit. These appear to stem
from a hydrogen bond in mol A between adenine atom N6
and atom O
c1 of a symmetry-related ThrB70 residue (the
same residue that affects Ap3A binding). This brings about a
3.4-A ˚ shift in the position of atom N6 and compensatory
adjustments to the remainder of the inhibitor (Table III). How-
ever, it has minimal effect on the 20-phosphate group, which
is particularly well ordered in the electron density map, sug-
gesting that it is the main focal point for binding. The 20-
phosphate hydrogen-bonds with His12, His119, Phe120, and
Gln11 (mol B only) (Figure 5, Table IV). There are also
water-mediated interactions between the inhibitor and
Gln11, Lys41, Gln69, Asp121, Val118 (mol A only), and
Asn71 (mol B only). The N
f atom of Lys7 is roughly equidis-
tant from the 20- and 50-a-phosphate groups; at 5.8–6.6 A ˚
away, it is somewhat more remote than in the other com-
plexes described in this report. The 50-a-phosphate makes no
hydrogen-bonding interactions with the protein and is ori-
ented toward the solvent, indicating that the nicotinamide
nucleotide portion is in a disordered, solvent-exposed state.
Given the similarity between the interactions of RNase A
(mol A)-bound pA-20-p and those of the visible portions of
NADPH/NADP
1, one might expect a correspondence in Ki
values. The literature contains no inhibition constant for the
RNase A pA-20-p interaction, but structural and kinetic data
FIGURE 5 RNase A NADPH complex (mol A). Shown are enzyme and inhibitor in the same
representation and orientation as in Figure 3. The side chains of V43 and E111 are drawn in dual
conformation (as ﬁtted to the electron density) whereas the side chain of V118 is omitted for
clarity. The inhibitor is disordered beyond the 50-a-phosphate.
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25 and Ang
45,46 indicate that it will be in the
region of that measured for pA-30-p (Ki 5 4.7 lM),
18 which
is indeed similar to that reported for NADPH. The present
data do not provide a structural basis for the 5-fold decrease
in afﬁnity that is measured when moving from NADPH to
NADP
1. It seems most likely that this is related to electro-
static repulsion of the cationic pyridinium ring of NADP
1
by the surplus of positive charge in the active site of the
enzyme, as suggested previously.
36
Although both NADPH and NADP
1 contain ppA-20-p as
a structural element, the adenylic portions of these dinucleo-
tides do not adopt the syn base (Class II) conformation
observed when ppA-20-p binds to RNase A in isolation.
20 It is
possible that the position and orientation observed for the
50-b-phosphate group of enzyme-bound ppA-20-p leave no
room for accommodation of an adjacent ribosyl group. This
differs from the corresponding portion of enzyme-bound
ppA-30-p
20 which has been shown to offer access to addi-
tional 50-linked substituents, e.g., those in pdUppA-30-p.
21
Structure of the RNase A PPi Complex
A pyrophosphate moiety is an invariant substituent of the
most potent nucleotide-based inhibitors identiﬁed to date.
Even as a free ion, it inhibits RNase A appreciably (Ki   170
lM),
47 highlighting its contribution to the afﬁnity of these
inhibitors. In the crystal structure of the RNase A PPi com-
plex, electron density for the ion is clear, particularly so in
mol B (Figure 2e). Both halves of the ion interact with the
protein via multiple direct and water-mediated hydrogen
bonds (Figure 6a). There is very little difference between the
two instances of the ion in the asymmetric unit. One half of
the ion (which we designate the a-phosphate) hydrogen-
bonds with Gln11 N
e2, His12 N
e2, His119 N
d1, and Phe120 N
FIGURE 6 RNase A PPi complex (mol B). (a) Enzyme and inhibitor in the same representation
and approximately the same orientation as in Figure 3. (b) Comparison with the Ang PPi complex
(PDB entry 1H52).
49 The two complexes were superposed on the basis of the C
a positions of key
nucleotide-binding residues (from RNase A, mol B: Q11, H12, K41, T45, H119, and F120; from
Ang: Q12, H13, K40, T44, H114, and L115). Shown in stereo from the same viewpoint as for panel
a are ball-and-stick representations of RNase A-bound PPi (colored as in panel a), Ang-bound PPi
(white), and neighboring Ang residues (green), along with a surface representation of Ang. Main
chain N, C, and O atoms of residues H8, Q12, H13, and K40 are omitted for clarity. Dashed lines
denote hydrogen bonds.
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f, which is
at a distance of 5.2 A ˚. The other half (the b-phosphate)
hydrogen-bonds with Lys41 N
f and Phe120 O (provided that
the relevant PPi oxygen is protonated). Water-mediated
hydrogen bonds are also made with Gln11 N
e2
(a-phosphate), Val43 O (b-phosphate, mol B only), Thr45 N
(b-phosphate), and Val118 O (a-phosphate, mol A only).
The position of the a-phosphate is a good match to that
of a conventionally-bound 50-a-phosphate such as that pres-
ent in pA-30-p or d(CpA)
22,34 and is an approximate match
to that of the 50-b-phosphate present in ppA-30-p, ppA-20-p
or 30,50-pyrophosphate-linked inhibitors such as pdUppA-30-
p.
20,21 The position of the b-phosphate does not correspond
well with that of any phosphate group among known inhibi-
tors. It is closest to that of the 50-c-phosphate in the Ap3A
complex (Figure 4a) but is further toward the B1 subsite.
The details of the RNase A PPi structure aid in the inter-
pretation of the nucleotide-binding properties of the homol-
ogous ribonuclease, Ang. Inhibitors of Ang have potential
therapeutic use as anti-cancer drugs (reference 8 and others
therein) but their binding has proved to be far less amenable
to crystallographic study owing to the obstructive position of
symmetry-related molecules in all crystal forms identiﬁed to
date and, in some cases, to the cryptic nature of Ang’s B1
subsite.
48 The largest entity that has been observed bound to
the active site of Ang is a PPi ion.
49 This binds in a position
that is very similar to that observed in the RNase A PPi com-
plex, with Ang residues Gln12, His13, His114, and Leu115
substituting for RNase A residues Gln11, His12, His119, and
Phe120, respectively (Figure 6b). The main difference between
the two complexes is the rotameric state of the b-phosphate,
which permits a hydrogen bond with Lys41 in RNase A but
not with its counterpart (Lys40) in Ang. The most likely cause
is the need to avert a clash with the C
c atom of Gln117 (a
component of the novel C-terminal segment of Ang) which,
when superposed, is located   2.5 A ˚ from the position occu-
pied by one of the b-phosphate oxygens in the RNase A com-
plex. The loss of this hydrogen bond may contribute to the
lower afﬁnity of PPi for Ang (Ki 5 1.7 mM).
49
DISCUSSION
Use of Monoclinic RNase A Crystals in the Study
of Inhibitor Binding
Since their discovery,
20 monoclinic RNase A crystals have
proven to be well suited to the study and development of
ribonuclease inhibitors. In their favor, they grow at low ionic
strength and moderate acidity, both of which are conducive
to nucleotide binding.
16 They also offer good access to the
whole B1-P1-B2 region of each of the protein molecules in
the asymmetric unit, as indicated by the excellent electron
density observed for enzyme-bound pdUppA-30-p.
21 The
quality of the present structures supports the utility of these
crystals but reafﬁrms one drawback, namely the potential
impact of symmetry-related protein chains on the binding of
inhibitors to the B2 subsite. Mol A is the most affected owing
to potential direct hydrogen-bonding interactions between
the inhibitor and a symmetry-related ThrB70 residue and, to
a lesser degree, to constrainment of GluA111 by its packing
against a symmetry-related TyrB115 residue. In addition,
GlnA69 and GlnB69 pack against one another, which could
conceivably constrain either residue. These features do not
affect the overall binding mode or conformational order of
the present inhibitors but they have been seen to do so, for
example in the binding of pA-20-p and dUppA.
22,27 In those
cases where there is a degree of conformational disorder and
an ensemble of inhibitor conformations exists (e.g., the bind-
ing of Ap3A, NADPH or NADP
1), the symmetry-related
contacts of mol A might be viewed as a helpful means of
selecting a representative conformation, but it may be that
mol B is a more reliable indicator of solution behavior.
Prospects for Improved Adenylic
Inhibitors of RNase A
The conformational diversity of RNase A-bound adenylic
inhibitors continues to expand. With our report of the RNase
A 50-ATP structure, there are now accounts of the binding of
50-a-, 50-b-, 50-c-, and 20-phosphates to the P1 subsite. The
torsional ﬂexibility of the nucleotides and the adaptability of
the B2 subsite are key factors. Despite the array of possible
conformations, the larger inhibitors investigated here (Ap3A,
NADPH, and NADP
1) are only partially visible in their re-
spective electron density maps. The possibility of nonenzy-
matic cleavage of these inhibitors must be considered. Ap3A
is known to be susceptible to hydrolytic cleavage within the
polyphosphate chain but the reaction yields products (50-
ADP and 50-AMP) that are smaller than the visible moiety
(50-ATP) and occurs at an insigniﬁcant rate (t½ 5 154 d at
608C, pH 6.0, and I 5 0.1).
50 For pyridine nucleotides under
mildly acidic conditions, polyphosphate cleavage is not a sig-
niﬁcant form of degradation. It does occur with oxidized
forms such as NADP
1 but elevated temperatures and alka-
line conditions are required for the detection of prod-
ucts.
51,52 In view of this, the partial electron density observed
in the present complexes most likely reﬂects a lack of interac-
tion between one half of the dinucleotide and the protein. It
appears that, as the complexity of the 50-linked extension
increases, the need to avoid unfavorable protein inhibitor
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mode and a reduced number of modes can support the bind-
ing of the compound.
The incomplete interaction of Ap3A, NADPH, and
NADP
1 with RNase A is reminiscent of the binding of Ap3A
and Ap4A to EDN.
24 With the latter enzyme, further exten-
sion of the polyphosphate linker to form Ap5A brought
about a far more extensive interaction, indicating that inclu-
sion of an appropriate linker can have a dramatic effect on
binding. Hence, it remains possible that the decreases in the
Ki for RNase A inhibition encountered when moving from
Ap3A( Ki 5 29 lM) through Ap4A( Ki 5 2.6 lM)t oA p 5A
(Ki 5 0.23 lM) reﬂect the formation of new interactions per-
mitted by linker extension, as previously suggested.
36
The details of the NADPH and NADP
1 complexes give
insight into the suitability of pA-20-p or ppA-20-p as a core
for the development of larger inhibitors of RNase A.
Although three different binding modes have been observed
for 20-phosphoadenosine-based nucleotides (Table I), none
of these permits binding of the nicotinamide portion of the
present nucleotides. As with the diadenosine polyphosphates,
the inclusion of extended, unbranched linkers may be neces-
sary to facilitate additional interactions beyond the 50-b-
phosphate.
Inhibitors of Speciﬁc Ribonuclease Subclasses
The development of inhibitors that are speciﬁc for individual
ribonuclease subclasses would be of great value to the study
of these enzymes in vivo and for the development of poten-
tial ribonuclease-directed therapeutics. High-throughput
screening has identiﬁed several non-nucleotide inhibitors
that bind slightly more tightly to Ang than to RNase A.
53
Existing adenylic inhibitors, on the other hand, tend to select
against Ang, for which they exhibit Ki values that are 2–3
orders of magnitude greater than those obtained for RNase
A.
16 With the nucleotides, the design process has been ham-
pered by an inability to obtain Ang inhibitor complexes in
crystalline form and it has been necessary to extrapolate
from data on RNase A and other enzymes. To help test the
validity of these measures, a direct comparison can now be
made between the RNase A PPi and Ang PPi structures.
49 It
is clear that the manner in which PPi binds to RNase A is not
an accurate indicator of what occurs when the same group is
O50-linked to an adenylic nucleotide. The same is true for
Ang, as can be deduced from heteronuclear NMR data on its
interaction with ppA-20-p and dUppA-20-p.
45 Although there
is a close correspondence in the ligand position in the RNase
A PPi and Ang PPi structures, there is a difference in the
manner in which the two enzymes bind ppA-20-p (Class II
and Class III modes, respectively). Nevertheless, with the
larger derivatives that have been examined (NADPH/NADP
1
with RNase A and dUppA-20-p with Ang), the Class III mode
prevails (as does the nonengagement of the second nucleo-
tide), suggesting that similar strategies may be necessary to
improve the afﬁnity of 20-phosphoadenosine-based nucleo-
tides for these enzymes.
It has been suggested that side chain differences located
toward the N-terminus of the protein could contribute to
differences in the afﬁnity of adenylic inhibitors for various
ribonucleases.
17 The contrast between the RNase A Ap3A
and EDN Ap3A structures supports this view (Figure 4b).
The complete conformational switch that is apparently trig-
gered by the Trp7 side chain of EDN highlights that such
steric effects can be strong and could be exploited in the in-
hibitor design process. In particular, the close proximity of
Trp7 to the ribosyl O30 atom of the inhibitor suggests that
O30-linked substituents above a certain size may not be toler-
ated well by this enzyme and may disfavor binding.
MATERIALS AND METHODS
Crystallization and Data Collection
RNase A and the sodium salts of 50-ATP, Ap3A, NADPH, NADP
1,
and PPi were obtained from Sigma and dissolved in water. RNase A
crystals were grown at 168C by the hanging-drop/vapor-diffusion
method as described previously.
20 These were transferred to a stabi-
lizing solution (25% PEG 4000, 0.02M sodium citrate buffer, pH
5.5) supplemented with either 100 mM 50-ATP, 100 mM Ap3A,
20 mM NADPH, 20 mM NADP
1, or 100 mM PPi at 168C for 24 h.
Diffraction data were collected at 100 K; for crystals soaked in 50-
ATP, NADPH, NADP
1, and PPi, this was carried out on stations
14.1, 9.6, 9.6, and 14.2 of the SRS, Daresbury, UK, respectively,
whereas for crystals soaked in Ap3A, this was conducted in-house
using a MAR Research 30-cm image plate mounted on a Rigaku
RU-H3R Cu Ka radiation source. All data were processed using the
HKL suite
54 and TRUNCATE.
55,56 Detailed data processing statistics
are given in Table II.
Phase Determination and Reﬁnement
Initial phases were determined using the molecular replacement
routines of AMoRe
57 with reference to coordinates of unliganded
RNase A obtained previously under the same crystal growth condi-
tions (PDB entry 1AFU).
20 Reﬁnement was conducted initially
using the rigid-body, simulated annealing, coordinate minimiza-
tion, and B-factor reﬁnement elements of CNS
58 and latterly using
the maximum-likelihood routines of REFMAC5.
39 Throughout, 5–
10% of reﬂections (depending on resolution) were set aside for
cross-validation.
37 After every reﬁnement cycle, electron density
maps were calculated and used to guide manual adjustments made
with either O or COOT.
59,60 Ligands or fragments thereof were
introduced on the basis of mFo-DFc maps and reﬁned using geo-
metrical restraints provided by the CCP4 monomer library.
61 Water
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peak heights exceeded 3r and where potential hydrogen bonds
could be made. Model validation was conducted with MolProbity.
40
Detailed statistics for each model are given in Table II.
Data Deposition: The coordinates and structure factors of RNase
A in complex with 50-ATP, Ap3A, NADPH, NADP
1, and PPi have
been deposited in the Protein Data Bank under accession numbers
2W5G, 2W5I, 2W5K, 2W5L, and 2W5M, respectively.
The authors thank the staff at SRS Daresbury and Drs Jawahar
Swaminathan and Ramanathan Natesh for their assistance with data
collection and archiving, and the Royal Society (UK) for an Indus-
try Fellowship to K.R.A.
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